NCT02453594View on ClinicalTrials.gov

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)

PHASE2CompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

June 10, 2015

Primary Completion Date

September 18, 2023

Study Completion Date

September 18, 2023

Conditions
Hodgkin Lymphoma
Interventions
BIOLOGICAL

pembrolizumab

IV infusion

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02453594 - Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) | Biotech Hunter | Biotech Hunter